Amgen EVP receives RSUs and stock options grant
Amgen Inc. executive David M. Reese reported routine equity compensation awards and a small tax-related share disposition.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Amgen Inc. executive David M. Reese reported routine equity compensation awards and a small tax-related share disposition. He received 2,912 shares of Common Stock as a grant on May 5, 2026, including 415 Dividend Equivalents, under Amgen’s Equity Incentive Plan. These Restricted Stock Units vest in four equal annual installments of 25% starting on May 5, 2027, with proration based on completed months of active employment in 2026, and will be settled in common shares on a one-to-one basis. He was also granted 19,002 non-qualified stock options at an exercise price of $329.59 per share, vesting in four equal annual installments of 25% beginning on May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 454 shares of Common Stock were disposed of at $329.59 per share to cover tax obligations, leaving him with 42,812 Common shares held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 454 | $329.59 | $150K |
| Grant/Award | Nqso (Right to Buy) | 19,002 | $329.59 | $6.26M |
| Grant/Award | Common Stock | 2,912 | $0.00 | $0.00 |
Footnotes (3)
- F1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027, subject to proration based on the number of completed months of active employment in 2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- F2. These shares include 415 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- F3. These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027, subject to proration based on the number of completed months of active employment in 2026.
Key Figures
Key Terms
Restricted Stock Units (RSUs) financial
Dividend Equivalents (DEs) financial
Equity Incentive Plan financial
non-qualified stock options financial
tax-withholding disposition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Amgen (AMGN) grant to EVP David Reese?
How do David Reese’s new Amgen (AMGN) RSUs vest and pay out?
What are the terms of David Reese’s new Amgen stock options?
What are Dividend Equivalents in David Reese’s Amgen RSU grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.